145918-75-8Relevant articles and documents
MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER
-
Page/Page column 14, (2021/10/22)
Use of lenvatinib, or a pharmaceutically acceptable salt thereof in combination with a compound of the formula MIV-818: (MIV-818) or pharmaceutically acceptable salt thereof, in the treatment of liver cancer or liver metastases. The respective dosage regimes of the compounds can be delivered concurrently or alternately.
DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER
-
Page/Page column 32, (2016/03/22)
The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
L-β-(2S,4S)- and L-α-(2S,4R)-dioxolanyl nucleosides as potential anti- HIV agents: Asymmetric synthesis and structure-activity relationships
Kim,Schinazi,Shanmuganathan,Jeong,Beach,Nampalli,Cannon,Chu
, p. 519 - 528 (2007/10/02)
In order to study the structure-activity relationships of L-(2S,4S)- and L-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents, various enantiomerically pure L-(2S,4S)- and (2S,4R)-dioxolanylpyrimidine and - purine nucleosides have been synthesize
